DekaBank Deutsche Girozentrale’s Fate Therapeutics FATE Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,000	Closed	-$158K	–	1274
2023 Q1	$158K	Sell	30,000 -10,000	-25%	-$60.3K	﹤0.01%	1213
2022 Q4	$398K	Hold	40,000	–	–	﹤0.01%	1088
2022 Q3	$887K	Buy	40,000 +11,550	+41%	+$334K	﹤0.01%	898
2022 Q2	$699K	Hold	28,450	–	–	﹤0.01%	958
2022 Q1	$1.13M	Buy	28,450 +2,600	+10%	+$101K	﹤0.01%	891
2021 Q4	$1.53M	Buy	25,850 +700	+3%	+$39.7K	﹤0.01%	838
2021 Q3	$1.5M	Sell	25,150 -20,000	-44%	-$1.57M	﹤0.01%	794
2021 Q2	$3.99M	Buy	45,150 +15,000	+50%	+$1.21M	0.01%	577
2021 Q1	$2.25M	Hold	30,150	–	–	0.01%	669
2020 Q4	$2.82M	Buy	30,150 +6,000	+25%	+$373K	0.01%	586
2020 Q3	$940K	Buy	+24,150	New	+$843K	﹤0.01%	772
2019 Q4	–	Sell	-25,000	Closed	-$387K	–	1164
2019 Q3	$387K	Sell	25,000 -25,000	-50%	-$479K	﹤0.01%	798
2019 Q2	$1.02M	Buy	+50,000	New	+$901K	0.01%	782
2019 Q1	–	Sell	-25,000	Closed	-$293K	–	1223
2018 Q4	$293K	Buy	+25,000	New	+$349K	﹤0.01%	914

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale's FATE Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 30,000 shares — an estimated $158K sold.

DekaBank Deutsche Girozentrale first reported a position in FATE in Q4 2018 and held it in 14 quarters. The position peaked at $3.99M in Q2 2021. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 30,000 Fate Therapeutics shares in Q2 2023, an estimated $158K.
DekaBank Deutsche Girozentrale first reported a position in Fate Therapeutics in Q4 2018 and held it in 14 quarters.
DekaBank Deutsche Girozentrale's Fate Therapeutics position peaked at $3.99M in Q2 2021.
188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.